ErVimmune
PrivateLast Round
Series A
Jan 21, 2026
Total Funding Raised
$7.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ErVimmune operates in Healthcare & Life Sciences and is based in Lyon. Its latest recorded funding round was a Grant round in November 2023.
ErVimmune is a biotechnology company developing therapeutic vaccines and cell therapies to treat cancers that do not respond to current immunotherapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ErVimmune Comparables
Compare ErVimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hervolution Therapeutics | 88% | |
| Nouscom | 84% | |
| Brenus Pharma | 82% |
For institutional investors. Book with your work email.
ErVimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 21, 2026 | ||||
| Grant | Nov 1, 2023 | ||||
| Seed | Jan 9, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ErVimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SPRIM Global Investments | Series A |
| EIC Accelerator | Grant |
| SPRIM Global Investments | Series A |
| Bpifrance | Seed |
| Seventure Partners | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 271% MoM, reaching 899.
- Jan 21, 2026
$20M raised in Series A financing.
For institutional investors. Book with your work email.
ErVimmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ErVimmune's valuation, stock price, and market status.
Is ErVimmune a public or private company?
ErVimmune is a private company.
What is the current stock price of ErVimmune?
ErVimmune is a private company, so its shares have no public market price. Caplight tracks ErVimmune's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ErVimmune worth (valuation)?
Valuation information for ErVimmune is not publicly available.
Can I buy ErVimmune stock?
ErVimmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ErVimmune's last funding round?
ErVimmune's most recent funding round was Series A on January 21, 2026.
Who are the main investors in ErVimmune?
Key investors in ErVimmune include SPRIM Global Investments, EIC Accelerator, SPRIM Global Investments, Bpifrance, Seventure Partners.
Will ErVimmune IPO soon?
No public IPO plans have been announced for ErVimmune.
How can I track ErVimmune secondary market activity?
Caplight tracks bids, offers, and trades in ErVimmune's shares on secondary markets.